Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity

Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and thus holds 180-day exclusivity on this strength, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2XF0inq
via IFTTT